Esophageal adenocarcinoma (EAC) is characterized by resistance to chemotherapy and poor outcome. Although Cisplatin (CDDP) has been used as a first-line therapy in patients with EAC, resistance remains a major clinical problem. The AXL receptor tyrosine kinase, originally isolated as a transforming gene from leukemia, is overexpressed in several solid tumors. Herein, we assessed AXL protein expression in human EACs and examined its role in CDDP resistance in human EAC cells. AXL overexpression was detected in >50% of tumors examined. Elevating AXL in non-overexpressing cells doubled the sensitivity to CDDP cytotoxicity and increased cell survival 3-fold, whereas attenuating AXL in ovexpressing cells reduced survival 2-fold. The effects of AXL modulation on cell survival associated with changes in cellular and molecular markers of apoptosis. Mechanistic investigations revealed that AXL blocked CDDP-induced activation of endogenous p73ɴ (TP73), reducing its protein half-life, and inhibited CDDP-induced levels of p-c-ABL(Y412) and p-p73ɴ(Y99). These changes were associated with a disruption of c-ABL/p73ɴ protein interactions due to association with c-ABL in the cytoplasm, thereby blocking nuclear accumulation of c-ABL and phosphorylation of p73ɴ in response to DNA damage. Together, our results establish that AXL promotes CDDP resistance in esophageal adenocarcinoma and argue that therapeutic targeting of AXL may sensitize these cancers to DNA damaging drugs.
Introduction
The incidence of esophageal adenocarcinoma (EAC) has sharply increased by 6-fold in the United States in the last few decades (1, 2) . One of the major risk factors for developing EAC is gastroesophageal reflux disease (GERD), which may lead to Barrett's esophagus, a known pre-malignant lesion that transforms into invasive cancer by progressing through intermediate stages of low-grade and high-grade dysplasia (reviewed by (3) ). Unfortunately, the majority of patients with EAC are mostly diagnosed at an advanced stage of the disease, which may reflect their poor prognosis (4) . Generally, the treatment of advanced EAC involves neo-adjuvant chemotherapy and radiation followed by esophagectomy (5) .
The cancer chemotherapeutic agent cisplatin (CDDP, cis-diamminedichloroplatinum) exerts its cytotoxic effect by inducing DNA damage and causing apoptosis through activation of the tumor-suppressor p53 protein (6) . Although deficient p53 expression renders cancer cells less responsive to cisplatin-based chemotherapy, drug resistance is not complete. In fact, the p73 protein, a member of p53 family, can also induce apoptosis in response to genotoxic stress (7) and cisplatin (6) . A previous study showed that cisplatin increased p73 protein levels through activation of the non-receptor tyrosine kinase c-ABL. Yuan et al, (8) demonstrated that c-ABL binds and phosphorylates the p73 protein on a tyrosine residue (Y99) in response to DNA damage, and disruption of the c-ABL/p73 interaction blocked apoptosis. Cisplatin alone or in combination with other drugs has been used in the treatment of patients with advanced esophageal cancer, but cisplatin resistance remains a serious clinical challenge (9, 10) . In addition to aberrant p53 expression, negative regulation of p73 could potentially play a significant role in promoting cisplatin resistance. This is of major importance given the fact that the majority of EACs are deficient or mutant in p53 (11, 12) .
The AXL receptor tyrosine kinase is a member of the TAM sub-family that also includes Tyro3 and Mer, and was originally isolated as a transforming gene from human leukemia cells (13, 14) . Elevated AXL expression and interaction with its ligand Gas6 (growth arrest-specific 6) have been associated with cell survival, proliferation, and migration in solid tumors (15) (16) (17) . These effects are mediated through activation of the MAPK/ERK and PI3K/AKT pathways (reviewed by Linger et al.) (18) . A recent study identified AXL activation as a novel mechanism of acquired resistance to EGFR inhibitors in non-small cell lung cancer (19, 20) . Overexpression of AXL has been reported in various neoplasms, including melanomas (21) , lung (22) , and breast cancers (23) . A previous study indicated that AXL was increasingly up-regulated during a multistep esophageal carcinogenesis and as an adverse prognostic marker in EAC (24) .
The primary aim of this report was to study the role of AXL in mediating CDDP resistance in EAC, and identify the molecular mechanism that regulates this effect. We have uncovered that the AXL protein is frequently overexpressed in human EAC primary tumors and cell lines. We also demonstrate that AXL suppresses c-ABL/p73 signaling in response to CDDP, thereby blocking apoptosis and promoting drug resistance in EAC. These findings provide evidence that AXL/c-ABL/p73 axis might be exploited as a therapeutic target to sensitize tumors to DNA-damaging drugs in EAC.
Materials and Methods

Cell lines and reagents
The human esophageal adenocarcinoma cancer cell lines OE33, OE19, SK-GT-4, and FLO-1 were kindly provided by Dr. David Beer (University of Michigan, Ann Arbor, MI). JHEsoAd1 cell line was a kind gift from Dr. James Richard Eshleman (Johns Hopkins, Baltimore, MD). The cells (OE33, OE19, SK-GT-4, FLO-1, and JH-EsoAd1) were evaluated weekly to ascertain conformity to the appropriate in vitro morphologic characteristics. Also, the tumorigenicity of the cells was authenticated by in vivo tumor growth in female athymic nude-Foxn 1 nu/nu mice (Harlan Laboratories). HEK-293 cells were purchased from ATCC (Manassas, VA). These cells were maintained in F12 (HAM) medium (GIBCO, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen Life Technologies, Carlsbad, CA) and 1% penicillin/streptomycin (GIBCO). The immortalized cell lines originated from normal esophageal squamous epithelia, HEEC, was purchased from ScienCell Research Laboratories (Carlsbad, CA); and EPC2, was kindly provided by Dr. Hiroshi Nakagawa (University of Pennsylvania, Philadelphia, PA). HEEC cells were cultured in EpiCM-2 medium (ScienCell) supplemented with 5% FBS. EPC2 cells were grown in keratinocyte SFM medium supplemented with 40 mg/ml bovine pituitary extract and 1 ng/ml epidermal growth factor (Invitrogen). The cell lines (HEK-293, EPC2, and HEEC) have not been authenticated. All the cells used in this study were not passaged longer than 6 months after receipt, and were confirmed free of mycoplasma as determined by MycoSEQ Mycoplasma Real-Time PCR Detection Kit (Applied Biosystems). Cisplatin (CDDP, cis-diamminedichloroplatinum) (APP Pharmaceutical, LLC., Schaumburg, IL) stock solution (3.3 mmol/L) prepared in sterile water was provided by TVC Outpatient Pharmacy, Vanderbilt University Medical Center, Nashville, TN. Cycloheximide was purchased from Sigma-Aldrich. AXL, PUMA, c-ABL, p-c-ABL(Y412), cleaved caspase-3 and -9, cleaved PARP, and ɴ-actin antibodies were obtained from Cell Signaling Technology (Danvers, MA). p-AXL(Y779) and HDM2 antibodies were purchased from R&D Systems (Minneapolis, MN) and Calbiochem (Billerica, MA), respectively. p73 antibody was obtained from Bethyl Laboratories (Montgomery, TX). Lamin B antibody was purchased Santa Cruz Biotechnology (Santa Cruz, CA).
AXL expression and plasmids
The constructs of pcDNA4/AXL-myc-His and pcDNA4 (a gift from Dr. Rosa Marina Melillo, University of Naples, Italy) (25) were utilized to generate stable expression cells. Briefly, OE33 cells were transfected using Iipofectamine 2000 (Invitrogen). Stably transfected OE33 cells expressing AXL or vector control (empty pcDNA4) were selected with 100 ʅg/ml zeocin (Invitrogen) following standard protocols (26) .
The AXL coding sequence from pcDNA3.1/AXL plasmid was sub-cloned into the adenoviral shuttle vector (pACCMV). The recombinant adenovirus-expressing AXL was generated by co-transfecting HEK-293 cells with the shuttle and backbone adenoviral (pJM17) plasmids using the Calcium Phosphate Transfection kit (Applied Biological Materials Inc., Richmond, BC). The pcDNA3/FLAG-p73ɴ and pcDNA3/GFP-c-Abl IV (mouse type IV) plasmids were kindly provided by Dr. Alex Zaika (Vanderbilt University Medical Center, Nashville, TN). The pcDNA3-lacZ plasmid was a gift from Dr. Michael K. Cooper (Vanderbilt University, Nashville, TN).
Small hairpin RNA
Lentivirus particles expressing control shRNA or a cocktail of five different clones of AXL shRNA were produced and validated by Sigma-Aldrich. FLO-1 cells that express high levels of endogenous AXL were transduced with lentivirus particles and selected with 1 μg/ml puromycin for 10 days.
Immunoblot analysis
Cells were lysed in RIPA buffer (50 mmol/L Tris-HCl buffer, pH 7.4, 150 mmol/L NaCl, 1% Triton X-100, 1% sodium deoxycholate, and 0.1% SDS) supplemented with 1x Halt protease inhibitor cocktail and 1x Halt phosphatase inhibitor cocktail (Pierce, Rockford, IL).
Proteins were separated and Western blot analysis was carried out as described previously (27) . 
Immunoprecipitation
Cells were lysed in RIPA buffer supplemented with 1% Halt protease and phosphatase inhibitors (Pierce). The protein concentration was determined by the Bio-Rad Protein Assay. Immunoprecipitations of equal total protein amounts (200 μg) were performed at room temperature for 1h by using a primary antibody previously bound to 50 ʅl Dynabeads Protein G (Invitrogen). The beads were washed three times with ice-cold PBS.
The beads in each tube were heated to 100°C for 5 min in 30 ʅl of 2x sample buffer. The proteins were then eluted by magnet and subjected to immunoblot analysis.
Immunohistochemistry
Tissue microarrays (TMA) containing 27 de-identified archival cases of esophageal adenocarcinomas, including 7 esophageal normal epithelial tissue samples, were kindly provided by Dr. Wael El-Rifai (Vanderbilt University Medical Center, Nashville, TN). 5 μm of TMA sections were used for IHC staining of AXL receptor tyrosine kinase with polyclonal goat AXL antibody (1:200) (AF154; R&D Systems). The intensity and frequency of staining were graded as described previously (28) . 
Cell viability assay
Clonogenic survival assay
Cells were plated in triplicate at low density (2x10 3 per well) in 6-well plates. The next day, cells were treated with vehicle or CDDP for 48h. Culture media were replaced and cells were grown for two weeks. Cell colonies were then fixed with 2% paraformaldehyde and stained with 0.05% crystal violet. Cell colonies were semi-quantitatively analyzed by densitometry using ImageJ software (NIH Image).
Apoptosis analysis
Cells ( regression was applied and the protein half-life (t 1/2 ) of p73ɴ, which is expressed as the time for degradation of 50% of the protein, was calculated from the fitted line equation (29).
Luciferase assay
To investigate the transcriptional activity of p73, we used the PG13-Luc vector that were normalized to ɴ-galactosidase levels.
Statistical analysis
The results were expressed as the mean with ± SD. The statistical significance of the studies was determined by either the parametric unpaired Student's t test or two-way ANOVA followed by Bonferroni post hoc test. Differences with ч0.05 are considered 
Results
Frequent overexpression of AXL in human esophageal adenocarcinoma
The Western blot analysis data indicated increased levels of AXL and p-AXL(Y779) proteins in 3/5 EAC cell lines, and 2/2 normal esophageal squamous cell lines were negative for AXL expression ( Figure 1A ). We evaluated AXL protein expression in tissue microarrays containing 27 EAC and 7 esophageal normal squamous tissue samples by immunohistochemical staining with anti-AXL specific antibody. The IHC data showed that AXL expression was relatively low in normal tissue samples, as depicted by weak membrane staining predominantly in the lower third of the mucosa ( Figure 1B, left panel) . In contrast, in some EAC tissue samples, AXL was highly expressed as indicated by strong cytoplasmic and membrane staining ( Figure 1B, right panel) . A comprehensive analysis of the IHC data, whereby IHC index cutoff of 3 was used to indicate overexpression, revealed that AXL was overexpressed in 51.8% of EAC tumor samples (14/27) ( Table 1 ). None of the tested normal tissue samples exhibited AXL overexpression (IHC index ч2) ( Table 1) . The difference in AXL protein expression between normal tissue samples and EAC was statistically significant (p= 0.0068).
AXL enhances cell survival in esophageal adenocarcinoma
The cell viability assay data indicated that reconstitution of AXL expression in OE33 cells significantly increased cell survival relative to control cells in response to 48h treatment with various concentrations of CDDP (p<0.05) (Figure 2A ). In fact, the CDDP IC50 was 45. 
AXL suppresses DNA damage-induced apoptosis and activation of caspases
The Annexin V/PI staining and FACS analysis data indicated that the reconstitution of AXL expression in OE33 cells inhibited early apoptosis events by 25% relative to control in response to CDDP (p=0.014) ( Figure 3A ). In line with this result, Western blot analysis indicated significantly higher protein levels of cleaved forms of caspase-9 and -3, and PARP in control cells than AXL-expressing cells after treatment with CDDP ( Figure 3B ). In contrast, knockdown of endogenous AXL in FLO-1 cells increased early apoptosis by 73.5% relative to control (p<0.01) in response to CDDP ( Figure 3C) showed that knockdown of endogenous AXL significantly increased protein levels of cleaved forms of caspase-9 and -3, and PARP relative to control in response to CDDP ( Figure 3D ). qRT-PCR analysis showed that relative mRNA expression of PUMA and HDM2 was 3.5-fold and 2-fold higher in control cells than AXL-expressing cells, respectively, in response to CDDP (Supplemental Figure 1) . To confirm the role of AXL in regulating p73 transcriptional activity, we performed the luciferase reporter assay using pG13-luc plasmid. In OE33 cells, luciferase activity was 54.7% higher in control cells than AXL-expressing cells (p=0.005) after treatment with CDDP ( Figure 4C ). Similarly, in OE19 cells, the luciferase activity was 81.1% higher in control cells than AXL-expressing cells (p=0.01) in response to CDDP ( Figure 4D ).
AXL blocks
Western blot analysis of cytosolic and nuclear protein fractions unequivocally confirmed CDDP-induced accumulation of p73ɴ protein in the nucleus in OE33 control cells ( Figure 4E ).
Conversely, CDDP treatment had no effect on p73ɴ level or localization in AXL-expressing OE33 cells ( Figure 4E ).
Based on our finding that AXL suppressed CDDP-induced activation of p73ɴ, we hypothesized that AXL could potentially regulate p73ɴ protein stability. To test this Indeed, the protein degradation data indicated that AXL significantly reduced the protein half-life of p73ɴ from 11.4h to 6.5h relative to control ( Figure 4F ).
AXL attenuates DNA damage-induced phosphorylation of c-ABL and disrupts c-ABL/p73 protein association
As the non-receptor tyrosine kinase c-ABL is the primary regulator of p73 in response to DNA damage, we postulated that AXL could negatively regulate c-ABL, thereby inhibiting Figure 6C ). Overall, the protein level of cytosolic c-ABL was significantly higher in AXL-expressing cells than control cells. Conversely, the nuclear c-ABL protein expression level was higher in control cells than AXL-expressing cells ( Figure 6C ).
In addition, the data showed that AXL protein expression was limited to the cytosolic fraction ( Figure 6C ). Taken together, these results strongly suggest that AXL sequesters c-ABL in the cytosol and prevents targeting of c-ABL to the nucleus in response to DNA damage.
Discussion
Although the DNA damaging agent CDDP alone or in combination with other drugs has been used as a first-line therapy in patients with advanced esophageal cancer, resistance to CDDP, unfortunately, remains a major clinical problem (9, 10) . Identification of the mechanisms that control resistance to CDDP is essential to predicting response to therapy, and to developing new drugs that can overcome resistance. Based on the fact that AXL was implicated in promoting cell survival and proliferation through activation of downstream growth and survival pathways in various cancers (15, 18) , we evaluated AXL protein expression and examined its role in CDDP resistance in EAC.
In this study, we demonstrated frequent overexpression of the AXL protein in EAC primary tumors (51.8%) and showed that AXL was exclusively expressed in EAC cell lines, but not in normal esophageal squamous cell lines. Our results clearly indicated that reconstitution of AXL expression enhanced survival and attenuated apoptosis after treatment with CDDP. Conversely, knockdown of endogenous AXL sensitized cells to CDDP.
Our findings strongly indicate that AXL promotes resistance to CDDP in EAC cells.
CDDP induces DNA damage causing apoptosis through activation of the tumor suppressor p53 protein (6) . However, CDDP can also induce apoptosis in p53-deficient cells through activation of the p73 protein, a member of the p53 family (6) . This is particularly of major importance, given the majority of EACs are deficient or mutant in p53 (11) . To identify the mechanism by which AXL mediates resistance to CDDP, we hypothesized that AXL could block activation of p73 in response to CDDP in EAC cells. Indeed, our data showed that the reconstitution of AXL expression significantly attenuated CDDP-induced transcriptional activation of endogenous p73ɴ as confirmed by decreased levels of p73ɴ, PUMA, and HDM2 proteins, and PG13-luc luciferase activity. Interestingly, AXL expression increased the basal CAN-12-3151 endogenous p73ɴ protein level, albeit blocking CDDP-induced activation of p73ɴ. This suggests that the reconstitution of AXL oncoprotein expression in our p53-deficient EAC cells could decrease growth rate or induce some apoptosis through activation of p73.
Consistent with this observation, our results indicated significantly less colony formation ( Figure 2C ) and more apoptosis ( Figure 3A ) in vehicle-treated AXL-expressing cells than control cells. A previous report showed that endogenous p73ɲ and p73ɴ proteins were upregulated in p53-deficient cancer cells in response to oncogenes (30) . Additional studies will be required to fully determine the mechanism by which AXL regulates endogenous p73 basal expression independent of stress signals. As the protein stability of p73 was shown to be enhanced by CDDP (6), we postulated that AXL could destabilize p73 protein, thereby blocking its activation in response to DNA damage. Indeed, we demonstrated that AXL expression significantly decreased the somewhat stable exogenous p73ɴ protein half-life from 11.4 h to 6.5 h.
Several studies indicated that the functional non-receptor tyrosine kinase, c-ABL, is required for CDDP-induced up-regulation of p73 protein stability, as activated c-ABL binds through its SH3 domain to the carboxy-terminal homo-oligomerization domain of p73 and phosphorylates it on a tyrosine residue at position 99 in response to DNA damage (6, 8, 31) .
We confirmed that AXL blocked CDDP-induced phosphorylation of c-ABL and p73ɴ proteins, and demonstrated that AXL expression disrupted c-ABL/p73ɴ protein association. Accordingly, our data showed that AXL significantly attenuated c-ABL-induced cell death, strongly suggesting that AXL regulation of p73 is mediated by c-ABL. c-ABL localization is controlled by three nuclear localization signals (NLS) and one nuclear export signal (NES) that are responsible for shuttling of c-ABL between the cytoplasm and nucleus (32) . It has been shown that nuclear c-ABL relays pro-apoptotic signals from ATM to p53 and p73 in response to DNA damage (8, 33) . Another study indicated that c-ABL increases p73 protein levels in the nucleus in a kinase-dependent manner. Phosphorylation of p73 (Y99) promotes tight interaction with the SH2 domain of c-ABL that may enhance p73 protein stability (34) .
Based on these studies and our findings, we postulated that AXL interacts with cytosolic c-ABL, thereby blocking nuclear accumulation of c-ABL in the apoptotic response to DNA damage. Our results clearly demonstrated protein association between AXL and either exogenous or endogenous c-ABL, although we did not confirm direct binding of AXL to c-ABL. Furthermore, we showed that AXL blocked nuclear accumulation of c-ABL protein in response to DNA damage, hence disrupting the apoptotic signaling cascade. In a similar study, Raina et al (35) indicated that the MUC1 transmembrane glycoprotein sequesters c-ABL in the cytoplasm and thereby attenuates apoptosis in response to anticancer agents mediated DNA damage. Interestingly, our data showed that AXL dramatically increased the basal protein expression level of c-ABL in the cytosol independent of DNA damage response.
Further studies will be necessary to elucidate the mechanism by which AXL regulates cytosolic c-ABL expression, and investigate its functional implication.
In conclusion, our results indicate that frequent overexpression of AXL in EAC underlies a CDDP resistance phenotype. We demonstrate that AXL expression inhibits c-ABL/p73 signaling in response to DNA damage, hence blocking apoptosis and mediating drug resistance in EAC. Therefore, our findings provide evidence that AXL/c-ABL/p73 axis could be exploited as a therapeutic target to sensitize tumors to DNA-damaging drugs in 
